1. Introduction
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality worldwide. Mild TBI (mTBI), also known as concussion, accounts for most TBI cases and is characterized by a transient alteration of consciousness or cognitive function. Despite the high incidence of mTBI, its pathophysiology remains largely unknown. In recent years, there has been a growing interest in the role of inflammation in the pathogenesis of mTBI [
1]. The prevalence of concussion varies across different populations and settings. In the general population, the estimated prevalence of concussion ranges from 1.6% to 3.8% [
2] with higher values in specific high-risk populations, such as athletes and military personnel [
3,
4]. The prevalence of concussions in high school athletes has been estimated to be as high as 11.2% [
5].
The inflammatory response is a complex process that involves the activation of various cell types, including microglia and astrocytes, and the release of a variety of pro-inflammatory and anti-inflammatory mediators. Studies have shown that the inflammatory response is activated early after mTBI and can persist for several weeks or months. Several inflammatory biomarkers have been proposed as potential markers of mTBI, including interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). Recent studies showed that these molecules could be found in increased concentrations in serum, cerebrospinal fluid (CSF), and saliva of the individuals that have undergone mTBI, in a severity and outcome dependent manner [
6,
7,
8]. While inflammation is characterized by the activation of immune cells and the release of inflammatory mediators, such as cytokines and chemokines [
9], in the context of concussion, it has been proposed as a possible contributor to the pathophysiology of the injury and persistence of symptoms in some individuals [
10].
Several studies have investigated the levels of inflammatory biomarkers in individuals with concussions and reported controverted results. While some studies reported increased levels of cytokines (IL-6 and TNF-α) in the serum or CSF [
7,
8], others did not observe significant differences in concussed individuals, as compared to age and sex-matched controls [
11,
12]. In this context, limited evidence on the utility of inflammatory biomarkers as predictors of clinical outcomes in concussion was provided. Several studies suggested that higher levels of inflammatory biomarkers may be associated with worse clinical outcomes, such as prolonged recovery or persistent symptoms [
8,
13], whereas other studies failed to confirm this association [
11,
12].
Thus, this study aims to provide an overview of the current knowledge on the role of inflammation in the pathogenesis of mTBI and the potential of some inflammatory biomolecules as biomarkers of mTBI. While summarizing the studies investigating inflammatory biomarkers in mTBI in diagnosis, prognosis, therapy, we will also discuss the limitations of the current literature and future directions for research in this field.
2. Materials and Methods
The aim of this meta-analysis was to examine the evidence on the association between inflammatory biomarkers and mTBI, as well as the potential utility of inflammatory biomarkers as diagnosis and prognosis tools in mTBI.
2.1. Search strategy
A systematic literature search was conducted using the PubMed, Embase and Cochrane Library databases. The search was limited to articles published in English from January 2000 to December 2021. The search terms used were "mild traumatic brain injury" OR "concussion" AND "inflammatory biomarkers" OR "cytokines" OR "chemokines" OR "CRP" OR "IL-1" OR "IL-6" OR "TNF-alpha". The reference lists of identified studies were also searched for additional relevant studies.
2.2. Selection criteria
Inclusion criteria for this meta-analysis were: (1) observational or interventional studies that examined the association between inflammatory biomarkers and mTBI or concussion; (2) studies that measured inflammatory biomarkers in serum or plasma; (3) studies that were written in English.
The exclusion criteria were considered: (1) case reports, case series, or reviews; (2) studies that did not measure inflammatory biomarkers in serum or plasma; and (3) studies that were not written in English or that were not available in full text.
2.3. Data extraction and quality assessment
Two reviewers independently screened the abstracts and full-text articles for eligibility and extracted data from eligible studies. Any discrepancies were resolved by mutual consensus. The following data were extracted from each study: first author, year of publication, study design, sample size, inflammatory biomarkers measured, and main findings.
The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for observational studies and the Cochrane Risk of Bias tool for randomized controlled trials (RCTs).
2.4. Data synthesis and analysis
Descriptive statistics were used to summarize the characteristics of the included studies. The effect sizes of the associations between inflammatory biomarkers and mTBI or concussion were calculated using standardized mean differences (SMDs) and 95% confidence intervals (CIs). Heterogeneity among the studies was assessed using the I2 statistic. Subgroup analyses were conducted based on the type of inflammatory biomarker (cytokine, chemokine, or other) and the study design (observational or RCT).
Statistical analysis was conducted using R software (version 3.6.2). A random-effects model was used to calculate the overall effect sizes due to the expected heterogeneity among the studies. The level of statistical significance was set at p < 0.05.
Publication bias was assessed using Egger's test and funnel plots. Sensitivity analyses were conducted by excluding studies with a high risk of bias and using a fixed-effects model.
4. Discussion
The role of inflammation in mTBI and PCS has recently been investigated by many studies. In the present meta-analysis, we investigated the role of inflammatory biomarkers in diagnosing mTBI and the prognosis of PCS: IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, and TNF-α.
IL-2 is a cytokine that plays a crucial role in the immune system by promoting the proliferation and activation of T cells and other immune cells being produced by various cells, including T cells, B cells, and natural killer cells, in response to antigen stimulation. IL-2 acts on cells that express the high-affinity IL-2 receptor (IL-2R) to promote cell growth, differentiation, and effector function. IL-2 has been implicated in a variety of physiological and pathological processes, including immune responses, autoimmunity, transplantation, cancer, and infectious diseases [
24]. Dysregulated IL-2 function can lead to various immunological disorders, such as immunodeficiency, autoimmune diseases, or chronic inflammation. Recent research data have also suggested a potential role of IL-2 in the pathophysiology of TBI and its associated symptoms. Although data from only one study only were available, the significant difference in IL-2 serum levels between controls and mTBI patients and a significant increase at six months post-injury suggested that it is equally involved in acute inflammatory response, contributing to the development of early symptoms and long-term recovery. Thus, IL-2 could be an important inflammatory biomarker of TBI diagnosis and PCS prognosis.
IL-1β is a pro-inflammatory cytokine primarily produced by activated macrophages and monocytes in response to infection, injury, or stress. IL-1β is involved in various physiological and pathological processes, including inflammation, fever, tissue repair, and immunity, acting on various target cells, including endothelial cells, fibroblasts, and immune cells, by binding to the IL-1 receptor (IL-1R) and activating intracellular signalling pathways. IL-1β promotes the production of other proinflammatory cytokines, such as TNF-α and IL-6, and induces the expression of adhesion molecules and chemokines, which attract immune cells to the site of injury or infection [
25]. Changes in IL-1β functions have been implicated in various diseases, including rheumatoid arthritis, type 2 diabetes, and Alzheimer's disease. IL-1β has also been implicated in the pathophysiology of TBI and its associated symptoms [
25]. The recent studies included in this meta-analysis suggested that the significantly increased IL-1β levels reported in mTBI patients associated with the acute phase of inflammatory response could indicate its role in the pathophysiology of mTBI, thus being a good candidate as a diagnosis biomarker. Furthermore, it was shown that IL-1b levels decreased six months after the injury suggesting a good potential in prognosis and outcome prediction.
IL-10 is an anti-inflammatory cytokine produced by T cells, B cells, macrophages, and dendritic cells. IL-10 plays a key role in regulating the immune response by inhibiting the production of proinflammatory cytokines, such as TNF-α and IL-1β, and promoting the differentiation and activation of regulatory T cells. IL-10 is involved in a wide range of physiological and pathological processes, including autoimmune diseases, allergies, infections, and cancer. Differences of IL-10 expression or function have been implicated in various immunological disorders, such as immunodeficiency, chronic inflammation, or cancer progression [
26]. The potential role of IL-10 in the pathophysiology of traumatic brain injury (TBI) and its associated symptoms has been investigated by several studies. However, the present meta-analysis failed to show a significant difference in the expression of IL-10 in patients with an mTBI compared to control individuals, and the role of this cytokine as a diagnostic or prognostic biomarker in mTBI seems to be insignificant.
IL-4 is a cytokine primarily produced by T helper 2 cells (Th2), mast cells, and basophils. It regulates the immune response by promoting the differentiation and activation of Th2 cells, inducing the production of IgE antibodies, and suppressing the activity of Th1 cells and macrophages. IL-4 is involved in several physiological and pathological processes, including allergy, asthma, autoimmunity, and infectious diseases. Dysregulated IL-4 expression or function has been implicated in various immunological disorders, such as allergic diseases, immunodeficiency, and autoimmune diseases. Although the levels of IL-4 were reduced in mTBI patients, and the result was statistically significant, sensitivity analysis failed to confirm the robustness of the result and further studies are needed to confirm the role of this cytokine as a diagnostic or prognostic biomarker in mTBI [
27].
Interleukins 6 and 8 are also proinflammatory cytokines that are primarily produced by immune cells, including macrophages, monocytes, and T cells, in response to infection, inflammation, or injury [
28,
29]. IL-6 acts on various target cells, including hepatocytes, lymphocytes, and endothelial cells, by binding to the IL-6 receptor (IL-6R) and activating intracellular signaling pathways. IL-6 promotes the production of acute-phase proteins, such as CRP, and the differentiation and activation of immune cells, such as Th17 cells and B cells. Various inflammatory or immune-mediated diseases, such as rheumatoid arthritis, multiple sclerosis, and cancer, were previously characterized by impaired IL-6 activity [
28]. In the present meta-analysis, we found that the levels of IL-6 were significantly different between mTBI patients and control individuals, a result that was also confirmed by the sensitivity analysis and indicating the potential role of this cytokine as a diagnostic and prognostic biomarker in mTBI. The levels of IL-8, however, were not significantly different. On the other hand, no clear information about the possible use of IL-8 was observed when we meta-analyzed the previous reports. Despite this, it is already known that the dysregulations of IL-8 expression or functions were seen in chronic obstructive pulmonary disease, cystic fibrosis, and sepsis [
30]. The recruitment and activation of neutrophils and other immune cells to the site of infection or injury, as well as endothelial cells and leukocytes activation, are concurring in the intracellular signaling pathways to which IL-8 participates. Kossmann et al [
31] discussed the possible implication of IL-8 in TBI when they observed that it is released into the CSF following a traumatic event resulting in brain injury. In this way, the non-specific participation of IL-8 to the TBI pathophysiology could be associated with blood-brain barrier dysfunction and nerve recovery [
31]. Notwithstanding, Whalen et al [
32] previously described IL-8 as a potential target in anti-inflammatory therapy and suggested that it participates in the main process undergoing the acute inflammatory component of TBI.
TNF-α and IFN-γ are proinflammatory cytokines primarily produced by activated immune cells, including macrophages, T cells, and natural killer cells, in response to infection, inflammation, or injury. TNF-α acts on various target cells, including endothelial cells, macrophages, and immune cells, by binding to the TNF receptor (TNFR) and activating intracellular signaling pathways. TNF-α promotes the production of other proinflammatory cytokines, such as IL-1β and IL-6, and induces the expression of adhesion molecules and chemokines, which attract immune cells to the site of injury or infection. TNF-α activities impairments have been reported in various inflammatory or immune-mediated diseases, such as rheumatoid arthritis, inflammatory bowel disease, and cancer [
33,
34]. The present study showed no significant difference between mTBI patients and controls, and therefore we conclude that blood TNF-a has no value as a diagnostic biomarker for mTBI.
Being a cytokine involved in regulating the immune response by promoting the differentiation and activation of Th1 cells, natural killer cells, and macrophages, it was showed that IFN-γ inhibits the proliferation and activation of Th2 cells and regulatory T cells. Dysregulated IFN-γ functions have been implicated in various immunological disorders, such as autoimmune diseases, chronic infections, and cancer [
35]. There was statistical significance in the serum levels of IFN-γ between mTBI and individuals without a history of mTBI. However, the data regarding IFN-γ is rather scarce, thus further analysis could shed more light onto this cytokine potential as a diagnosis or prognosis biomarker.
The data on the difference of the serum inflammatory biomarkers at 6- and 12-months post-injury were limited, and no clear conclusions can be made.
Overall, these findings suggest that inflammatory biomarkers may serve as potential diagnostic and therapeutic targets for mTBI. Further research is needed to understand better the role of these biomarkers in the pathophysiology of mTBI and to explore their potential as diagnostic or therapeutic tools. Additionally, identifying specific cytokine profiles associated with different mTBI symptom clusters may improve diagnosis and treatment efficacy.